openPR Logo
Press release

US Antidiabetics Drug Market Outlook 2022 Report Download

01-11-2018 08:42 AM CET | Health & Medicine

Press release from: Kuick Resarch

US Antidiabetics Drug Market Outlook 2022 Report Download

“US Antidiabetics Drug Market Outlook 2022” report gives clinical and non-clinical insight on trends associated with the development of Antidiabetics drug market in US. Report helps to identify the diabetes epidemiology (Prevalence of Type 1 and 2 Diabetes) in the US market along with the associated economic burden and productivity loss.

“US Antidiabetics Drug Market Outlook 2022” report highlights:

* US Diabetes Epidemiology
* US Antidiabetics Market Overview
* Key Marketed Antidiabetic Drugs in US
* US Biosimilar Insulin Market
* US Antidiabetics Drug Market Future Prospects

Download Sample

For Report Sample Contact: neeraj@kuickresearch.com

Report Weblink: https://www.kuickresearch.com/report-us-antidiabetics-drug-market-outlook-2022.php

Table of Contents

Antidiabetics: Regimen for Diabetes Mellitus
1.1 Prologue Towards Diabetes
1.2 Preface to Antidiabetics

Antiquity of Managing Diabetes Mellitus
2.1 Trajectory from Diabetes to Insulin
2.2 Historical En Route towards Oral Diabetic Medication

Treatments Available for Diabetes Mellitus
3.1 Non-Pharmacological Approaches for Diabetes Mellitus
3.2 Pharmacological Approaches for Diabetes Mellitus

Cataloguing of Antidiabetic Agents
4.1 Antidiabetic: Oral Agents
4.1.1 Biguanides
4.1.2 Thiazolidinediones (TZDs)
4.1.3 Sulfonylureas
4.1.4 Meglitinides
4.1.5 andalpha;- Glucosidase Inhibitors
4.1.6 Dipeptidyl Peptidase-4 Inhibitor
4.1.7 Bile Acid Sequestrants (BAS)
4.1.8 Dopamine Agonist-2

Antidiabetic: Injectable Drugs
5.1 Insulin: A life saving Modality
5.2 Non-Insulin Alternatives for Diabetes Mellitus

US Diabetes Epidemiology
6.1 Prevalence of Type 1 and 2 Diabetes
6.2 Economic Burden Associated with Type 1 and 2 Diabetes: Productivity Loss and Medical Bills

US Antidiabetics Market Overview
7.1 Antidiabetic Injectable Market Trends in US
7.2 Antidiabetic Oral Drugs Market Trends in US
7.3 Commending Trends of Antidiabetics

US: Key Marketed Antidiabetic Drugs
8.1 Insulin Degludec (Tresiba)- Injection
8.2 Insulin Lispro - Injection
8.3 Insulin Inhalation(Afrezza) - Inhalation
8.4 Insulin Glargine (Toujeo) - Injection
8.5 Insulin Glulisine (Apidra) - Injection
8.6 Insulin Aspart (NovoLog) - Injection
8.7 Insulin Detemir (Levemir FlexTouch) - Injection
8.8 Insulin Glargine (Lantus) - Injection
8.9 Insulin Aspart/Insulin Protamine Aspart (NovoLog) - Injection

US Biosimilar Insulin Market: Glargine Basaglar andndash; The First “Biosimilar” Insulin
9.1 First Insulin Biosimilar
9.2 Impact of Basaglar Launch

US Antidiabetics Drug Market Dynamics
10.1 Accelerative Parameters
10.2 Major Challenges

US Antidiabetics Drug Market Future Prospects

Competitive Landscape
12.1 AstraZeneca
12.2 Bayer
12.3 Boehringer Ingelheim
12.4 Eli-Lilly
12.5 Johnson and Johnson
12.6 Merck
12.7 Novartis
12.8 Novo Nordisk
12.9 Sanofi
12.10 Takeda

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release US Antidiabetics Drug Market Outlook 2022 Report Download here

News-ID: 895181 • Views: 236

More Releases from Kuick Resarch

Bi-specific Antibodies For Enhanced Killing of the Foreign Cells Invaders
The availability of bi-specific antibodies has triggered a fundamental shift in the treatment paradigm for broad spectrum disease. The big pool of data available for the complex human system and its coupling with the advanced analytics tools have helped the researchers to come up with a treatment procedure that is unique and hold maximum promising outcomes for the huge percentage of patient population in the world. Bi-specific antibodies represent
Artificial Immune Modulation Therapy, An Upcoming Breakthrough in the Global Imm …
The platform provided by artificial immune modulation therapy comprises of a specific artificial matrix for the modulation of different antigen-presenting cells, which is an important part in the immune system. The methodology involved in the artificial immune modulation therapy represents simple yet powerful action against challenging mechanism of the cancer development and progression. The therapy involves engineering and administration of the artificial presenting cells to the patients so that
Exploitation of Immune Cells for Gaining Maximum Positive Outcomes in Cancer Mar …
The approach that has been focused by the cancer immunotherapies have helped in transforming the global cancer therapeutics market. Its arrival in the market has assisted the researchers to overcome all the challenges and short-imperative approach that has been delivered by the other commercially available cancer therapies. The fundamental principle of the immunotherapy which involves the cells of the immune cells holds great potential and huge difference in delivering promising
Global Cell Therapy Market To Surpass US$ 400 Billion In Opportunity By 2027 Wit …
"Global Cell Therapy Market, Therapy Price, Dosage & Clinical Trials Insight 2027" Report Highlights: • Global Cell Therapy Market Opportunity: More Than USD 40 Billion By 2027 • Cell Therapy Clinical Trial Insight by Indication, Company and Country • Global Cell Therapy Clinical Pipeline: 1000 Cell Therapies • Globally Marketed Cell Therapies: 25 Cell Therapies • Cell Therapy Trials For COVID-19: 10 Cell Therapies • Global COVID-19 Cell Therapy Clinical Trials By Phase & Company • COVID-19 Impact Analysis on Global market &

All 5 Releases


More Releases for Antidiabetic

Oral Antidiabetic Treatment Market to Record Sturdy Growth by 2025
Diabetic is the condition where the sugar (glucose) level is high in the blood or the production of the insulin is inadequate. Diabetes main type the very first one is Type 1 and the second is Type 2, both the diabetic are most commonly find in the current scenario, apart from this many other diabetics case are also been listed as gestational diabetes and others. The world is moving
Oral Antidiabetic (OAD) Treatment Market Snapshot by 2017 – 2025
Diabetic is the condition where the sugar (glucose) level is high in the blood or the production of the insulin is inadequate. Diabetes main type the very first one is Type 1 and the second is Type 2, both the diabetic are most commonly find in the current scenario, apart from this many other diabetics case are also been listed as gestational diabetes and others. The world is moving toward
Global Antidiabetic Drugs Market - Product Segment Analysis And Forecast
Diabetes is a major lifestyle disorder affecting millions of individuals globally. The disorder is also linked with other complications such as diabetic retinopathy, diabetic foot ulcers, nephropathy and cardiovascular complications among others. Wide spread global prevalence and rising incidence rate has made the antidiabetic drugs market attractive for pharmaceutical drug manufacturers. Introduction of superior products in the recent past and increasing patient compliance are other factors driving the diabetes treatment
Antidiabetic Biosimilars Market Expected to Grow Globally
Antidiabetic biosimilars market overview Antidiabetics help control blood glucose levels in diabetic patients. Various types of antidiabetics include biguanides, thiazolidinediones, DPP-IV inhibitors, α-glucosidase Inhibitors, sulfonylureas, insulin, and GLP-1 receptor agonists such as exenatide. A biosimilar product is biological product that is approved on the basis that it is highly similar to a FDA approved biological product known as a reference product. Biosimilar manufacturers need to generate data from lab testing and
03-07-2017 | Health & Medicine
SA-BRC
Antidiabetic Drugs Market and Pipeline Assessment
Diabetes is a major lifestyle disorder affecting millions of individuals globally. The disorder is also linked with other complications such as diabetic retinopathy, diabetic foot ulcers, nephropathy and cardiovascular complications among others. Wide spread global prevalence and rising incidence rate has made the antidiabetic drugs market attractive for pharmaceutical drug manufacturers. Introduction of superior products in the recent past and increasing patient compliance are other factors driving the diabetes treatment
Global Antidiabetic Thiazolidinediones Market Research Report 2017
The research report on the global Antidiabetic Thiazolidinediones market studies the market in the past based on which estimates are presented for the future. The report looks into vital market indicators, trends, and opportunities that will have a bearing on the development of this market. The report begins with an outline of terms and terminologies, classifications, and applications that are standard conventions in the global Antidiabetic Thiazolidinediones market. A glance into